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ABSTRACT 
The heart falls in love and helps with decisions, but it couldn’t do either without sufficient oxygen, and on demand. The 
capability of blood vessels to supply the heart muscle (myocardium) with that oxygen, called myocardial oxygenation, is 
the critical determinant of cardiac function. Impairment of myocardial oxygenation is a defining feature of ischemic heart 
disease (IHD), which afflicts millions of people around the world. IHD is caused by pathological conditions that affect the 
blood vessels supplying oxygen to the heart muscle. Methods for detecting myocardial oxygenation deviations from the 
norm are routinely sought to guide interventions (medical, surgical or lifestyle) and to prevent acute life-threatening 
events such as heart attacks (myocardial infarction). Despite their importance, efforts to attain noninvasive methods for 
ascertaining myocardial oxygenation have not yet been realized.  Instead, the current diagnosis of IHD still relies on 
surrogate metrics, which are either non-specific, operator dependent, or require ionizing radiation or contrast agents 
(injected dyes): many patients are accordingly contraindicated.  Two decades ago, an oxygenation-sensitive CMR 
approach was used to demonstrate that CMR signals can be sensitized to changes in myocardial oxygenation. But 
physiological and imaging noise during CMR data acquisition persistently limited the ability to detect small changes in 
oxygenation-sensitive CMR signals in the heart, impeding its adoption. Here, we demonstrate a CMR-based approach 
(cfMRI denoting cardiac functional MRI) that jumps the barrier, finally allowing reliable detection of myocardial 
oxygenation. It does this by (a) advancing a natural molecule (carbon dioxide), for repeat interrogation of the functional 
capacity of the heart’s blood vessels; (b) developing a fast MRI approach suitable for clinical adoption, to efficiently 
gather time-resolved oxygenation-sensitive signals throughout the heart, without being limited by key confounders 
(cardiac/respiratory motion and heart-rate changes, etc.); and (c) integrating the multiple whole-heart images within a 
computational framework, to statistically reduce noise and arrive at confidence maps of alterations in myocardial 
oxygenation. At a minimum, cfMRI enables evaluation of IHD for those currently contraindicated for current state-of-the-
art imaging: it does not require ionizing radiation, contrast agents or needles (venous cannulations). It may even prove 
beneficial for general application, as cost, side effects, and risk of adverse events may be less. At a maximum, cfMRI 
permits monitoring of myocardial oxygenation, which opens the potential to observe previously unattainable image data 
to enhance our current understanding of cardiac physiology and pathophysiology. This has the potential to broaden our 
ability to noninvasively identify those at risk for IHD and a diverse spectrum of heart diseases related to myocardial 
ischemia.  
 
 
 
 
 
 
INTRODUCTION 
Ischemic heart disease (IHD) is the leading cause of death in the Western world (1). It often stems from atherosclerotic 
narrowing of the coronary arteries (stenosis), leading to reduced blood flow and oxygen supplied to the heart muscle 
(myocardium). This causes myocardial ischemia during physical exertion, a condition where the oxygen supply to the 
heart muscle does not meet the myocardial oxygen demand (2). The presence and extent of myocardial ischemia are key 
predictors of major adverse cardiac events (MACE), including stroke, heart attack (myocardial infarction) and death (1). 
Early interventions (medical, surgical or lifestyle), guided by the extent and severity of ischemia, are crucial for reducing 
MACE in IHD patients (3-5). Yet, to date, there are no reliable noninvasive methods to evaluate the presence or severity 
of deficiencies in meeting myocardial oxygen demands.  
  Given the lack of viable methods to assess myocardial oxygenation, the diagnosis of IHD has become entrenched 
in the use of a surrogate metrics, notably electrocardiography (ECG) or myocardial blood flow (MBF). Among these, the 
determination of ongoing myocardial ischemia based on ECG changes is attractive since ECG assessment is highly 
accessible. Yet, ECG may be non-specific, can be normal in patients during an ischemic event and cannot identify 
asymptomatic patients with significant coronary stenosis unless combined with exercise stress, which is not tolerated by 
more than 50% of IHD patients (6). Methods based on MBF are the most widely used for the assessment of IHD and one 
that is recommended by the American Heart Association. MBF changes can be determined using multitudes of clinically 
available imaging methods, including single-photon emission tomography (SPECT), positron-emission tomography 
(PET), first-pass perfusion cardiac magnetic resonance imaging (MRI) and contrast-enhanced echocardiography (7). 
These methods are often combined with exercise stress or intravenously injected stress agent (e.g., adenosine), to assess 
ischemic burden (extent and severity). In their use, these methods suffer from one or more problems that limit diagnostic 
capabilities and, ultimately, patient outcomes. For example, SPECT and PET approaches are used in more than 90% of 
the nearly 10 million myocardial ischemia-testing studies in the US (1), but they require radioactive tracers, which pose 
incremental risk to patients (8). Other methods, such as first-pass perfusion MRI, are free of ionizing radiation but require 
intravenously delivered exogenous contrast media, based on gadolinium (7), which are contraindicated in millions of 
people in the US with chronic kidney disease (9). More recently, a T1-based MRI method that does not require exogenous 
contrast agents or ionizing radiation, likely based on impairments in myocardial blood volume, has been demonstrated in 
IHD patients (10). However, because oxygen supply and demand to a given physiological stimulus are variable in every 
patient, measuring MBF may not provide full physiological insight into the extent and severity of myocardial ischemia in 
patients with IHD (11). Further, there are pathological conditions where perfusion is normal but oxygenation is impaired 
(12) (13). For all of these reasons, the quest for  development of a non-invasive method has been actively pursued by 
researchers. 
 To assess IHD based on myocardial oxygenation without ionizing radiation or exogenous contrast media, blood-
oxygen-level-dependent (BOLD) cardiac MRI (BOLD-CMR) has been investigated (14). The evidence that BOLD-CMR 
changes are primarily based on myocardial oxygenation was presented nearly two decades ago (15, 16). This led to 
several pilot clinical validation studies, testing the method’s feasibility (12, 17, 18). However, the state-of-the-art BOLD-
CMR approach has been shown to perform poorly against the current “state of the art” PET (12). It is not known whether 
this discrepancy is real (i.e., a true one between a test for myocardial oxygenation and a test for myocardial blood flow) or 
whether it is a consequence of known accuracy limitations of BOLD-CMR. Without a reliable approach to assess 
myocardial oxygenation, there is no way to directly evaluate the method’s status in IHD,  its relationship to myocardial 
blood flow, and its potential for diagnosis for new, “at-risk” patients, where impaired oxygenation does not accompany 
detectable abnormalities in blood flow. 
 Uncertainty of a measurement is fundamentally determined by noise. In BOLD-MRI, physiological noise 
(motion) and imaging noise (limitations in signal-reception elements, termed “RF coils”) dominate the small signal 
changes that result from oxygenation level changes. This makes it challenging to accurately index an observed signal 
change against blood oxygenation. The realization that the uncertainty of a measured signal can be reduced if the response 
can be repeatedly modulated by a known stimulus (19), was a major breakthrough for BOLD-MRI in the brain (functional 
MRI, abbreviated as fMRI)) and it enabled sensitivity required for accurate detection of oxygenation changes. Notably, 
this key innovation has enabled fMRI to revolutionize our understanding of neural processes over the past two decades 
(20). Though this approach for defeating the critical noise limitations of BOLD-CMR is appealing, translating it into 
practice for myocardial oxygenation assessment is far from simple. Unlike in the brain, where the vasoactive stimulus is 
easily repeatable because it is visual or cognitive, injectable drugs (e.g., adenosine) are used to stimulate changes in the 
heart and these cannot be repeatedly administered within the same examination due to adverse side effects (21). To 
statistically uncover the underlying BOLD-CMR signals in the heart, rapidly acquired images registered across multiple 
stimulations, as well as whole-heart BOLD-CMR images are required. However, state-of-the art BOLD-CMR is 
essentially two-dimensional: it is typically limited to a single slice, because whole-heart three-dimensional acquisitions 
that are sensitive to oxygenation cannot be completed within the time that pharmacological agents are administered. The 
current acquisition schemes are also sensitive to heart-rate variations between different vasodilatory states. This means 
they can contaminate the BOLD-CMR signal readouts by masking the signal associated with true physiological changes 
in blood flow.   
 Herein we show that these challenges can be overcome through scientific advances in coronary vasodilation, 
technical advances in data acquisition, and integration and analyzation of the results in a computational framework. 
Specifically, we demonstrate that it becomes possible to accurately detect healthy and myocardium affected by coronary 
narrowing without contrast agents or ionizing radiation when (a) the heart is repeatedly stimulated with a physiologically 
tolerable and prospectively targeted increase in arterial CO2 (PaCO2); (b) the heart is rapidly imaged with a time-efficient, 
confounder-corrected whole-heart, free-breathing BOLD-CMR approach; and (c) the resultant BOLD-CMR images are 
integrated (registered and segmented) and analyzed to arrive at statistical parametric maps. We refer to this approach as 
cardiac fMRI (abbreviated as cfMRI); the concept is summarized in Fig. 1. We demonstrate the capabilities of cfMRI in a 
large, clinically relevant animal model with and without coronary stenosis. It is exciting that cfMRI opens the door for 
accurately imaging myocardial oxygenation. Accordingly, this method can potentially enable noninvasive examination of 
IHD in millions of people, without exposing them to ionizing radiation or exogenous contrast agents. This is done based 
on the true parameter determining ischemic heart disease, namely impairments in oxygenation and opens the door to 
uncovering insights into myocardial oxygenation that were previously not accessible.  
 
 RESULTS 
Repeat Stimulation for Enabling Robust Myocardial BOLD MRI: Proof-of-Concept Using 2D BOLD-MRI 
Previous studies have shown that arterial CO2 tension when increased by 25 mmHg from baseline levels can accentuate 
myocardial blood flow by more than 2-fold, a hallmark of potent coronary vasodilators (22); and that such changes can be 
identified with 2D myocardial BOLD-CMR.  However, studies to determine whether repeat exposure of the heart to a 
predefined CO2 stimulus can be used to improve the detection of healthy and hypoperfused myocardium with or without 
coronary stenosis have not been reported. To fill this gap in knowledge, we studied this in two parts. First, we performed 
experiments in dogs exposed to repeat modulation of arterial CO2  (normocapnia, end-tidal CO2 (PETCO2) = 35 mmHg; 
and hypercapnia PETCO2 = 60 mmHg) and free-breathing 2D BOLD-CMR to assess whether the repeat stimulations can 
identify healthy myocardium in dogs (n=5) without coronary stenosis when the resulting BOLD responses are averaged. 
Next, we performed studies in the same dogs subjected to coronary stenosis (n=5) to identify whether ischemic territories 
can be identified following repeat modulation of arterial CO2  (normocapnia, PETCO2 = 35 mmHg; and hypercapnia 
PETCO2 = 60 mmHg) and 2D BOLD-CMR on the basis of signal averaging to reduce image noise. We validated our 
findings against simultaneously acquired 13N-ammonia PET.   
 Typical results from healthy dogs (i.e. without coronary artery stenosis) exposed to intermittent hypercapnia 
(established with prospective control of PaCO2; Fig. 2A) in an animal are shown in Fig. 2B. To investigate the dynamic 
myocardial BOLD response as a function of PaCO2 in each myocardial segment, we acquired BOLD images of the mid-
ventricular myocardium and segmented images according to the American Heart Association (AHA) 6-segment model 
and measured the BOLD response in each segment (Fig. 2, panel B1). Every segment showed elevated BOLD response 
during the hypercapnic stimulations that were absent during normocapnia. When this was repeated (i.e. animals were 
subjected to repeat hypercapnia and normocapnia), the pattern of BOLD response was reproducible across all segments. A 
map of BOLD response observed following administration of paired PaCO2 modulation (defined as hypercapnia followed 
by normocapnia) is shown in Fig. 2, panel B2. The average BOLD response acquired following four repeat stimulation of 
hypercapnia and normocapnia is shown in Fig. 2, panel B3. Average myocardial BOLD response derived following 
multiple stimulations was more homogeneous and higher in magnitude compared to a single stimulation. This observation 
was consistent with myocardial blood flow changes observed with 13N-ammonia PET (Fig. 2, panel B4). 
         To examine whether this approach could be used to improve the identification of myocardial territories subtended by 
a significant coronary stenosis, we surgically controlled the left-anterior descending coronary artery (LAD) diameter by 
adjusting the Doppler flow velocity of the vessel as previously described(23).  Subsequently we exposed each animal to a 
single and multiple PaCO2 stimulations during which time, 2D BOLD-MRI and 13N-ammonia PET scans were acquired. 
BOLD response observed in each segment of the mid-ventricular myocardium (segmented according to the AHA 
recommendation) was measured. Typical BOLD response that we observed in an animal is shown in Fig. 2, panel C. 
Myocardial BOLD response to hypercapnia was strong in segments 1 to 5, but not in segment 6 (Fig. 2, panel C1).  Maps 
of BOLD response observed following single PaCO2 stimulation was relatively heterogeneous (Fig. 2, panel C2), but the 
average BOLD response following four repeat stimulations showed a confined region of impaired BOLD response 
consistent with the LAD territory (Fig. 2; panel C3), which was consistent with 13N-ammonia PET (Fig. 2, panel C4). 
Fast, Free-breathing, Whole-Heart Myocardial BOLD-MRI with Repeat Hypercapnic Stimulations for Accurate 
and Objective Identification of Myocardium Perfused by Healthy Coronary Arteries  
While repeat hypercapnic stimulations combined with 2D BOLD-CMR and signal averaging can significantly improve 
the visualization of standard, single-stimulation, BOLD-CMR, it has practical limitations. First, with this approach the 
BOLD responses need to be visually delineated which introduces subjectivity into image analysis. Second, 2D CMR 
acquisition schemes are limited by (a) inadequate speed to fully image the heart multiple times to accommodate repeat 
hypercapnic stimulations; (b) irrecoverable cardiac motion between multiple acquisitions leading to misregistration errors; 
and (c) undesirable contributions from T1 weighing, coil bias, breathing motion and heart rate dependency, all of which 
confound the BOLD response. Collectively, these limitations can compromise both sensitivity and specificity of BOLD-
CMR. We addressed these key limitations in two steps.  
In the first step, we performed numerical simulations by considering a range of peak BOLD signal responses and 
associated noise, to estimate whether the confidence in detecting myocardial BOLD response can be improved by 
increasing the number of measurements in a statistical test employing repeated measures Analysis of variance (ANOVA). 
The results (Fig. 3) showed that the statistical confidence (p<0.05) in identifying the presence of a BOLD response is 
directly related to the maximal dynamic range of the response available and the number of repeat measurements. 
Specifically, it identified that for a given average myocardial BOLD response in the heart, typically ~10%(23), more than 
3 repeat measurements would be needed to objectively identify the healthy myocardial territories. This model provides the 
basis for developing a statistical framework for objectively discriminating between myocardial regions that are responsive 
to a given stimulus from those that are not on the basis of repeat measurements. 
To address the second limitation, we developed a fast free-breathing 3D T2 mapping technique at a magnetic field 
strength of 3T that is insensitive to heart-rate changes between rest and stress states, which would support repeat imaging 
of the whole heart under multiple hypercapnic/normocapnic stimulations.  We then performed in-vivo studies in healthy 
canines (n=8) under repeat hypercapnic/normocapnic stimulations. Subsequently we analyzed the observed BOLD 
response within an ANOVA framework to derive statistical parametric maps of p-values.  
 The framework of the data acquisition protocol, image acquisition and reconstruction strategy, and statistical 
analysis used to analyze the BOLD images is summarized in Fig. 4. The data acquisition protocol under time-varying 
PaCO2 (i.e. alternating between normocapnia and hypercapnia) is shown in Fig. 4A. The confounder-corrected T2 CMR 
pulse sequence (magnetization preparation, time-efficient k-space sampling, motion-corrected T2 mapping) that we 
developed for rapidly imaging the whole-heart under hypercapnic stimulation is shown in Fig. 4B (panels B1-B3). We 
used the T2 values to assess the BOLD response.  Fig. 4C shows representative whole-heart BOLD response from a dog 
under a single hypercapnic/normocapnic stimulation using the new imaging sequence. A mid-ventricular BOLD response 
from the same animal acquired under similar conditions, using the standard short breath-held 2D BOLD-CMR, is shown 
for reference. The myocardial BOLD response from the 2D and 3D approaches were similar, albeit both approaches 
showed significant heterogeneity of response. Fig. 4D shows the statistical framework we used to identify the healthy 
myocardial territories.   To achieve this, animals were subjected to repeat hypercapnic/normocapnic stimulations. The 
whole-heart T2 images at each state of PaCO2 acquired under hypercapnic/normocapnic conditions were registered to the 
initial 3D myocardial T2 maps acquired under normocapnia using non-rigid registration (Advanced Normalization Tools, 
ANTs) (24). Subsequently, animals underwent repeat hypercapnic/normocapnic stimulations. The whole-heart images 
were segmented according to the recommendation of AHA. Segmental myocardial T2 values acquired under normocapnia 
and hypercapnia were compared using all the segments (hypercapnia and normocapnia pair) with ANOVA statistics to 
test the null hypothesis:  
H0 [Null: BOLD response absent]: T2 during normocapnia = T2 during hypercapnia 
H1 [Alternate: BOLD response present]: T2 during normocapnia ≠ T2 during hypercapnia. 
Null hypotheses were rejected when p<0.05.  The segmental p-values from repeated measurements one-way ANOVA 
were used to create statistical parametric maps (SPM) as shown in Fig. 4D. In these maps, myocardial segments with p 
<0.05 were the segments showing statistically significant BOLD response to hypercapnia following one or more 
hypercapnic stimulation(s). 
Using this approach, we studied healthy dogs exposed to intermittent hypercapnia. A representative case from this 
study is shown in Fig. 5A, where the segmental p-values were mapped following each stimulation as SPM. Note that, 
although there is marked heterogeneity in BOLD response following a single stimulation, with each repeat stimulation, 
the statistical confidence in observing a BOLD response increased and became homogeneous across the heart. A direct 
comparison between the results in Fig. 5A, averaged across all AHA segments as a function of number of stimulations, is 
shown along with 13N-ammonia PET map of myocardial perfusion reserve (MPR) in Fig. 5B. The mean and standard-
deviation of the p-values observed following each stimulation derived across all myocardial segments of the heart 
decreased with each repeat stimulation as shown in Fig. 5, panel B1. On the basis of PET images, the MPR derived under 
hypercapnia and normocapnia in the same animal and imaging session confirmed the absence of perfusion deficits and 
uniform vasodilatory response across the left ventricle (Fig. 5, panel B2). The collective findings of SPM across all 
animals, following single and quadruple stimulation blocks, along with mean 13N-Ammonia PET MPR are shown in Fig. 
5C (panels C1 and C2), respectively.  Following a single stimulation, there is marked heterogeneity in p-values suggesting 
that healthy myocardium can be mischaracterized to be non-responsive likely due to dominance of noise over small 
BOLD signal change; however, with repeat stimulation, the noise and thus the errors, are significantly reduced.   These 
results support the notion that when repeat hypercapnic stimulations are combined with confounder-corrected fast 3D 
BOLD-MRI, it is possible to substantially increase the confidence in detecting healthy myocardial territories without 
contrast agent or ionizing radiation at levels that are realized with the gold-standard, 13N-ammonia PET.  
 
Accurate Detection of Myocardial Segments Subtended by Clinically Significant Coronary Stenosis with Statistical 
Parametric Maps Derived Using 3D Myocardial BOLD-MRI and Repeat Hypercapnia 
In the previous section, we demonstrated that BOLD response can be accurately detected in healthy myocardium using an 
approach which integrates the results from a fast 3D technique, repeat hypercapnic stimulation, to arrive at statistical 
parametric maps. However, whether this approach can be used to identify myocardial territories affected by a functionally 
significant coronary stenosis is not known. To address this gap and test whether our approach can be extended for 
identifying reversible perfusion defect territories, we performed additional studies in the same dogs (n=7) that underwent 
3D acquisitions in the absence of coronary stenosis. Animals were studied with non-flow limiting LAD coronary stenosis 
and underwent repeat stimulations (4 blocks; each block consisting of hypercapnia and normocapnia) and whole-heart 
BOLD images were acquired at each of the hypercapnic and normocapnic states in a similar manner to Fig. 4A. As before, 
hearts were registered using ANTs(24) and the myocardium was segmented according to the AHA recommendation. The 
statistical framework was applied using the same hypothesis tests as outlined in the previous section to identify remote 
(i.e. unaffected/healthy) myocardial territories. The p-values were then used to construct SPMs of the heart.  
 The findings from this study are summarized in Fig. 6.  Panel A, from a representative animal with LAD stenosis 
shows the myocardial SPM along the long- and short-axis orientations of the heart, along with standard bull’s eye 
representation based on AHA segmentations. Note the significant heterogeneity in BOLD response throughout the 
myocardium following single stimulation and the convergence of two myocardial territories with increasing number of 
stimulations. The spatial localization of these territories was visually concordant with the 13N-ammonia PET MPR (Fig. 
6B) following repeat stimulation. The segmental territories identified to be remote and affected based on 13N-ammonia 
PET MPR showed distinct statistical characteristics. For the case in Fig. 6A, mean and standard-deviation of the p-values 
of all remote territories were significantly lower than the affected territories independent of the number of stimulations. 
Notably the p-values of the remote territories quickly converged to low values after the second hypercapnic stimulation 
and reached statistical significance by the fourth hypercapnic stimulation. However, the affected territories retained high p 
values and were heterogeneous despite the increasing number of stimulations. These observations were consistent with the 
spatially observed differences in MPR based on 13N-ammonia PET and consistent across all animals (Fig. 6C). We found 
that regardless of the number of stimulations, nearly all measurements showed a sensitivity that is >80% in identifying the 
affected myocardium. However, the specificity for identifying healthy myocardium was only 36% with a single 
stimulation and with each additional stimulation, the specificity increased significantly, reaching 92% following the fourth 
stimulation. A similar observation was evident with accuracy: while the accuracy after a single stimulation was 49%, with 
each increasing stimulation, the accuracy increased substantially and reached 91% following the fourth stimulation. These 
results support the notion that a statistical parametric mapping, which is enabled by repeatedly stimulating the heart with 
prospective control of the PaCO2 and fast, 3D whole-heart T2 mapping, can markedly increase the accuracy of BOLD-
CMR for identifying hypoperfused myocardial territories to levels observed with 13N-ammonia PET.  
 
DISCUSSION 
Accurate identification of myocardial territories affected by coronary artery disease is critical for managing patients with 
ischemic heart disease. Current methods used for this purpose however, require ionizing radiation or exogenous contrast 
media. In the best case, these methods expose patients to incremental risk; and in the worst case, they are contraindicated. 
Previous efforts to address these limitations, particularly on the basis of myocardial BOLD-CMR, have made important 
progress; however, clinical adoption of it remains uncertain due to limited reliability. In this work, we demonstrated how 
it is possible to overcome this key obstacle through a new approach, which identifies the affected and healthy/remote 
myocardial territories using a statistical framework. This is enabled by intermittent hypercapnia to repeatedly stimulate 
myocardial blood flow and rapid, free-breathing whole-heart T2 mapping to acquire BOLD images, and a computational 
platform to perform motion-corrected registration and segmentation. Our investigation, performed using a clinically 
relevant animal model, systematically demonstrates through a set of progressively advancing studies how this can be 
accomplished. In the first study, using a 2D T2 CMR with limited spatial coverage (single, short-axis slice), we show that 
repeat modulation of myocardial blood flow changes in the heart with hypercapnia allows visual identification of (a) the 
healthy myocardium in animals without coronary stenosis; and (b) the affected and remote myocardial segments in 
animals with coronary stenosis. To overcome the spatial coverage and registration limitations inherent to the 2D approach, 
we developed a time-efficient, confounder-corrected, whole-heart T2 mapping that can be performed under free-breathing 
conditions. We then applied this imaging approach with rapid prospective control of PaCO2 to generate whole heart 
myocardial BOLD images under hypercapnia and normocapnia. These datasets were then registered together and analyzed 
segmentally in a statistical framework to demonstrate that SPMs can be generated to accurately identify the healthy 
myocardium in animals without coronary narrowing. Finally, we extended the approach in animals with controlled 
coronary artery stenosis so that it can be used to objectively identify healthy and affected myocardium in the setting of 
clinically significant coronary stenosis with unprecedented sensitivity, specificity and accuracy; all above 90%.   
Our study assessed segmental changes in myocardial perfusion based on the changes in myocardial oxygenation 
associated with clinically significant coronary stenosis. While this is sufficient to meet the current clinical need in the 
setting of coronary artery disease, expanding this approach to pixel-wise assessment of myocardial oxygenation would 
open the door for testing novel physiological hypotheses surrounding IHD that are yet to be proven. For instance, pixel-
wise cfMRI could be used to evaluate alterations in microcirculatory oxygenation, which could empower the assessment 
of microvascular disease, where the myocardial blood flow to the subendocardium is believed to be impaired even in the 
absence of occlusive coronary disease. Current methods do not have the capacity to confirm or refute this since the 
available methods rely on washout kinetics of the contrast medium and not oxygenation. Hence, pixel-wise assessment of 
myocardial oxygenation enabled by cfMRI can be instrumental for accurately discerning whether the transmural changes 
in blood flow and oxygenation occur in parallel. Such an understanding could provide new insights that can improve our 
understanding of how angina develops in patients with microvascular disease and evaluate therapies to alleviate 
microvascular impairments in oxygenation. Studies of this nature are likely to demand more advanced segmentation and 
registration approaches so that pixel-wise analysis can be accurately performed. We anticipate that these demands can be 
met with novel segmentation and registration algorithms that are actively being developed for cardiac image analysis (25). 
Additionally, to enable pixel-wise SPM, additional studies would be required to determine the number of minimum 
stimulations necessary for accurate assessment of BOLD signal changes at the pixel level.  
There are multiple other conditions where cfMRI could be useful as well. cfMRI identifies the affected regions of 
the myocardium as those regions that do not respond to repeat hypercapnic stimulation. Although we used this approach 
to identify territories affected by stenosis of a single coronary vessel, we anticipate that this approach can be applied to 
other patterns of coronary artery disease as well. Specifically, this approach may be extended for identifying clinically 
significant multi-vessel coronary artery disease, which is believed to result in balanced ischemia. In addition, cfMRI may 
also be used to examine changes in myocardial oxygenation of non-ischemic origin, such as hypertrophic heart disease, 
which is known to impair myocardial oxygenation reserve (13). Moreover, although our studies showed that cfMRI can 
identify substantially reduced blood flow and oxygenation, identification of early changes in myocardial oxygenation 
(e.g., from subclinical level of coronary stenosis or early changes in the heart due to hypertrophy) would require 
additional studies. We anticipate that these studies would benefit from refined statistical hypotheses and/or selection of 
optimal statistical thresholds that build on identifying myocardial territories of interest based on cfMRI. 
Finally, given the lack of invasive or non-invasive methods to directly assess myocardial oxygenation in vivo, we 
demonstrated the capacity of cfMRI to accurately identify myocardial territories affected by coronary stenosis on the basis 
of 13N-Ammonia PET under identical physiological conditions. Nonetheless, the tapering off in sensitivity and specificity 
between cfMRI and 13N-Ammonia PET at ~90% can be suggestive of the potential differences between flow and 
oxygenation. Further studies would be needed to probe the conditions under which myocardial oxygenation and flow 
changes are congruent or different. 
 Other methods to assess IHD without contrast agents or ionizing radiation are under development or are emerging 
(10, 26). Amongst these, spectroscopic CMR approaches have the capacity to offer insight into myocardial oxygenation, 
but they have not been successfully translated into clinical practice due to poor reliability (27). Additionally, a recent 
study employing native T1 CMR has successfully demonstrated that IHD can be identified without exogenous contrast 
agents or ionizing radiation (10). While this this approach appears promising, randomized multi-center studies to evaluate 
the capacity of native T1 CMR for diagnosis of IHD in spectrum of patients presenting with the disease is likely needed 
prior to its widespread adoption.  
 
Practical Aspects of Translating the Proposed Approach into Clinical Setting 
The proposed method builds on previous studies from our laboratory and elsewhere, which show that tolerable levels of 
hypercapnia leads to more than 2-fold increase in myocardial blood flow and similar modulation in oxygenation in extent 
to that observed with adenosine (commonly used coronary vasodilator) in both in dogs and in humans (22) (28). Although 
our findings in this study are limited to canines, given that all cardiac stress testing paradigms have been first successfully 
demonstrated in dogs, and 25-mmgHg increase in PaCO2 is tolerable in humans, we anticipate that the proposed approach 
would translate well in humans. To date, hypercapnia has been shown to be safe and tolerable in a broad spectrum of 
patients (age range 9 to 88) (29). Further, hypercapnic stimulus in conjunction with imaging has been extensively studied 
in patients with neurovascular disease(29). Accordingly, there is precedence for using hypercapnia in patients. 
Given the growing availability of MRI systems, the infrastructure costs required to translate the proposed 
approach into the clinical settings, which already have access to MRI suites, is expected to be minimal (costing less than 
1% of the total cost of the scanner environment). Further, since the proposed strategy does not require contrast agents, 
infusion pumps etc., it would yield substantial cost savings to the medical centers relative to the status quo. Although, a 
direct translation of the proposed approach in the current state is expected to take ~40 minutes in human subjects, 
compared to the ~10-15 minutes of imaging duration with standard methods, methods that can reduce scan time (for e.g., 
through faster data acquisitions taking advantage of spatio-temporal redundancies in conjunction with utilization of 
generalized linear models for signal analysis), are expected to permit the proposed approach to be executed within the 
standard duration of cardiac stress tests. This would also limit the hypercapnic durations to a much shorter time (<4 
minute). 
 Although a 25-mmHg increase in PaCO2 is expected to be tolerable by most people, some may find it 
uncomfortable, which may be addressed by taking advantage of the flexibility cfMRI offers for fine tuning image 
acquisition and analysis.  For example, in patients who could tolerate only a lower hypercapnic stimulus, based on Fig. 2, 
a greater number of weaker hypercapnic stimulations may offer a viable alternative. When this is combined with 
accelerated data acquisition strategies to yield images of higher temporal resolution to deploy advanced statistical methods 
that automatically find thresholds of affected regions in a multivariate fashion, it may be possible to identify myocardial 
territories supplied by stenotic coronary arteries, even in subjects with lower tolerance for hypercapnia (30). Alternatively, 
in patients who are able to tolerate a 25-mmHg of stimulus but cannot tolerate multiple repeat stimulations of it, an 
alternative may be rapid acquisition of images under other waveforms of PaCO2 (e.g. ramps instead of blocks or shorter 
frequency with longer duration of hypercapnia), which are all possible with the proposed prospective control of PaCO2.  
 Although the proposed approach has notable strengths, it is not without limitations. First, while the existing 
methods utilize pharmacological stress, contrast media and/or ionizing radiation, cfMRI requires a gas controlling system, 
which is an additional expense and one that may require a skilled operator for gas control, albeit this individual may be no 
different than one who is typically present during standard pharmacological stress tests, such as a nurse practitioner. 
Moreover, given that the proposed approach relies on PaCO2 to alter the vasodilatory capacity of the coronaries, the 
capability of the approach in subjects with respiratory disorders (asthma, chronic pulmonary disorder, etc.) in whom IHD 
is suspected is unclear and requires careful investigation. Finally, the proposed approach requires a clinical MRI system 
with high performance hardware and software, which although is becoming common, it is not always within reach for 
everyone.     
In spite these limitations, the proposed approach opens the door to new opportunities for cardiac stress testing in 
some of the most vulnerable patients. First, cardiac stress testing may be enabled in adult patients with renal insufficiency, 
who would otherwise receive multiple doses of ionizing radiation, which can expose them to greater risks associated with 
radiation. Next, it offers an alternative to patients who are not candidates for exercise or intravenously administered 
vasodilatory agents as part of stress tests. Further, it may enable cardiac stress testing in the children without ionizing 
radiation, contrast agents, pharmacological stress or needles. Accordingly, there is substantial motivation to translate the 
proposed approach not only to incrementally improve existing care but also to enable management of IHD in those who 
are contraindicated for standard cardiac stress tests. 
     
CONCLUSION 
cfMRI enables non-invasive determination of healthy myocardium and myocardium affected by reversible perfusion 
defects due to coronary stenosis on the basis of myocardial oxygenation with unprecedented reliability. This integrated 
approach has the capacity to open a new paradigm for a radiation-, contrast- and needle-free approach for accurately 
determining reversible perfusion defects in patients suspected of having functionally significant coronary artery disease. 
Further, it has the desirable characteristics to access multiple other myocardial pathologies on the basis of oxygenation.  
 
MATERIAL and METHODS 
In the text below we provide an abbreviated version of the Materials and Methods. A more detailed version of the 
methods including data analysis and statistical tools employed can be found in the Supplementary Material.  
Animal Preparation and Method for Inducing Coronary Stenosis 
Dogs (N=15, 20-25 kg) were studied with and without surgically induced coronary stenosis. All animals were studied 
according to the NIH “Guide for the Care and Use of Laboratory Animals” following approval of Institutional Animal 
Care and Use Committee.  In a subset of the animals, a left lateral thoracotomy was performed as previously described by 
our group (22). A Doppler probe was attached distal to the first branch of the left anterior descending coronary artery 
(LAD) to enable measurement of coronary blood flow velocity (CBFV).  An externally actuated hydraulic occluder was 
affixed proximal to the Doppler flow probe. Subsequently, the chest was closed, and the animals were allowed to recover 
for at least 7 days prior to imaging studies. Prior to all imaging studies, animals were fasted, sedated, intubated and 
anesthetized. During the imaging studies, anesthesia was maintained with a continuous infusion of propofol.  Dogs were 
transferred to the PET/MR scanner table and were mechanically ventilated through the RespirAct™ (Thornhill Research 
Inc, ON, Canada) with parameters reported in previous studies(23). In stenosis studies, coronary stenosis was induced 
prior to commencing imaging. The perfusion level during rest and stress were confirmed with 13NH3 PET images. Prior to, 
or right after, the baseline (PETCO2 = 35 mmHg) and peak hypercapnia (PETCO2 = 60 mmHg) BOLD acquisitions, the 
Doppler transducer (Triton Technology Inc, CA, USA) was connected to the wires originating from the surgically 
implanted Doppler probe and root-mean-square Doppler flow velocity values were recorded.  In dogs where LAD stenosis 
was to be induced, peak hyperemic coronary blood flow velocity was measured at PETCO2 = 60 mmHg was reduced to 
coronary blood flow velocity measured at PETCO2 = 35 mmHg to provide a standardized hemodynamically effective 
constriction that does not decrease blood flow below baseline flow under resting conditions (normocapnia).   
 
Modulation of Arterial Pressure of CO2 
Prospective targeting of PaO2 and PaCO2 was implemented using a validated gas controlling system (RespirActTM). The 
principles of controlling end-tidal gases have been previously described (31). In this study, we targeted hypercapnia at 
PaCO2 = 60mmHg with PaO2 = 130 mmHg; and normocapnia at PaCO2= 35 mmHg with PaO2 = 130 mmHg. These targets 
were synchronized with cardiac MR (CMR) and PET acquisitions. Before each image acquisition, PaCO2 level were 
stabilized at the targeted level for 1 minute to ensure that target PaCO2 values were reached.  Physiologic response to the 
stimulations is summarized in Table SM-1.  
 
Imaging Protocol 
In all imaging studies, 13N-ammonia PET and BOLD CMR images were simultaneously acquired a clinical PET/MR 
scanner.  In animals without coronary stenosis, PET images were acquired under rest and hypercapnia (6 mins) to quantify 
the MBF under different physiological conditions. A time delay was introduced between sequential PET acquisitions at 
each physiological condition to ensure sufficient decay of each 13N-ammonia dose (5 half-lives, ~50 minutes). Following 
the first PET scan, 4 sets of prospectively targeted normocapnia and hypercapnia stimulations were induced using 
RespirActTM. The PaCO2 levels were maintained for 5 minutes during each physiological state (Fig. SM-1). BOLD CMR 
images were acquired 1 minute after reaching the targeted PETCO2 level. In animals with coronary stenosis, baseline blood 
flow prior to surgery was compared to baseline flow post-surgery (on the day of stenosis studies) using 13N-ammonia 
PET. LAD coronary stenoses were induced before the first PET acquisition. Other aspects of the imaging protocol were 
similar to that implemented in intact animals. A schematic representation of the time course of execution of the study 
protocol is shown in Figure SM-1. During repeat stimulations, two BOLD acquisition methods (2D and 3D T2 maps) 
were used in a subgroup of animals. In 2D studies (N=5 for both intact and stenosis groups), a conventional 2D T2 
mapping sequence was prescribed over a mid-ventricular slice. Images were acquired under short breath holds (<10 s) at 2 
minutes and 5 minutes after target PETCO2 values were reached. In the 3D acquisitions, the proposed 3D sequence was 
prescribed under free breathing conditions starting 1 minute after the targeted PETCO2 level was reached.  
 
MRI Pulse Sequence Development 
A heart-rate independent, free-breathing, 3D T2 mapping prototype sequence with whole-heart LV coverage, which 
minimizes the sensitivity to B0 and B1 inhomogeneities was developed for the PET/MR system. Adiabatic T2 preparation 
with spoiled gradient-echo (GRE) readout was used to minimize B0 and B1 artifacts that are otherwise prominent at 3T 
and confound BOLD signal readouts. To improve imaging efficiency and enable data acquisition under free-breathing 
conditions, a motion-correction platform with a hybrid Cartesian-radial trajectory was applied that permits near perfect 
imaging efficiency.  To further increase acquisition speed and minimize the signal dependence on heart rate between rest 
and stress, a Saturation Recovery (SR) preparation was integrated with a constant saturation recovery time (TSR) to reset 
longitudinal magnetization in every heartbeat (32-34). To minimize any potential confounding effects associated with 
differences in T1 recovery following T2 preparation under rest and stress (10), data was collected and centrically encoded 
in the through-plane direction. Images were acquired with 3 incremental T2-prepation times (TE=0, 24, 55ms) and T2 
maps were reconstructed using a custom-written Matlab (The Mathworks, Natick, Massachusetts) script. The accuracy of 
the proposed approach were studied with computer simulations and ex-vivo tissue preparations. These and the data CMR 
acquisition parameters are detailed in Supplementary Material. 
 
Assessment of MBF with simultaneously acquired 13N PET  
All PET images were acquired in 3D list mode using 13N-ammonia (100 MBq, IV bolus (30 s) followed by 10 cc saline 
flush) as the blood flow tracer.  Prior to each PET scan, MR images were acquired to correct for photon attenuation.  A 2-
point Dixon MR imaging pulse sequence was used for segmentation and attenuation correction.  PET data was acquired 
over 10 minutes and was started a few seconds before the 13N-ammonia injection. In animals without coronary stenosis, 
images were acquired during hypercapnia and at normocapnia to determine the MBF response in the absence of coronary 
stenosis. In animals with coronary stenosis, images were acquired at rest and during hypercapnia after infliction of LAD 
stenosis. The MRI attenuation map and PET images were aligned and adjusted by an experienced technologist. Dynamic 
PET images were reconstructed with different time periods (twelve 10-s, two 30-s, one 1-min, and one 6-min frames, for a 
total of 10 min). Images were reconstructed with 3 iterations and 3D post filtering with a 5-mm Gaussian kernel. Data 
were reconstructed with 2-mm pixels for each dynamic frame. Myocardial blood flow (MBF; ml/min/g) were derived 
from the PET data using the automated QPET software (Cedars-Sinai Medical Center, Los Angeles, CA, USA), as shown 
previously (35).  
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Figure Captions: 
Figure 1: Cardiac fMRI. A schematic showing the three key aspects of cardiac fMRI (scientific and technical advances, and a 
computational framework) that are employed to enable accurate detection of myocardial oxygenation changes.  
 
Figure 2. Repeat Stimulations and Image Averaging for Enhancing Myocardial BOLD Response. Prospective Control of PaCO2 
(A1 and A2): Panel A1 shows the system used for prospectively modulating PaCO2 and Panel A2 shows the trace of achieved PaCO2 
levels during the scans; Healthy Animal without Coronary Stenosis (B1-B4): Panel B1 shows segmental BOLD response in AHA 
segments 1 through 6 in a healthy animal during the first four blocks of intermittent hypercapnia (4 stimulations), which highlights the 
dynamic signal response during the repeat stimulations. Panel B2 shows the spatial maps of the BOLD response in the mid-ventricular 
myocardium after one hypercapnic stimulation and Panel B3 shows the spatial map of the mean BOLD response following 4 
hypercapnic stimulations. Panel B4 shows the 13N-ammonia PET response (myocardial perfusion reserve) acquired simultaneously 
with BOLD-MRI. Animal with Coronary Stenosis (C1-C4): Panel C1 shows that typical segmental BOLD response across AHA 
segments 1 through 6 during four blocks of intermittent hypercapnia (4 stimulations) from an animal with significant LAD coronary 
stenosis. Panel C2 shows the spatial maps of the BOLD response in the mid-ventricular myocardium after one hypercapnic stimulation 
and Panel C3 shows the spatial map of the mean BOLD response following 4 hypercapnic stimulations. Panel C4 shows the 13N-
ammonia PET response (myocardial perfusion reserve) acquired simultaneously with BOLD-MRI. 
 
Figure. 3. Theoretical Basis for Objective Assessment of Myocardial BOLD Response: Figure shows the relation between BOLD 
response (vertical axis) and the number of stimulations (horizontal axis) required to establish statistical significance (color-coded p-
values). For a given BOLD response, the number stimulations required for reliable assessment (p<0.05) of a change from baseline 
condition lies at the right of the white dotted line. For example, to reliably detect a BOLD response with peak BOLD signal response 
of 10%, greater than 3 measurements are needed. The color bar on the right provides the scale for p values associated with statistical 
significance. 
 
Figure. 4 Cardiac fMRI Framework Integrating MRI, Hypercapnic Stimulation and Statistical Analysis. (A) Data Acquisition 
Framework: The approach used to acquire 3D MRI under periodic changes in PaCO2 (normocapnic and hypercapnic conditions), 
preceded by a short-delay (stabilization period) to ensure that the acquisitions are only triggered once the desired PaCO2 are reached. 
(B) Time-efficient, free-breathing, confounder-corrected whole-heart T2 mapping: The timing diagram and data encoding strategy are 
illustrated in Panels B1 and B2, respectively. B1 shows a T2 preparation scheme composed of composite adiabatic RF pulses and 
spoiled gradient echo readout are used to minimize B1 and B0 artifacts at 3T. A saturation-recovery (SR) preparation was added to 
eliminate the signal dependence on heart rate between segmented readouts and navigator pulses were added to monitor the respiratory 
motion during acquisition. B2 shows the centric-encoding scheme with hybrid trajectory to ensure optimal T2 weighting. B3 shows the 
motion-correction algorithm and T2 mapping using a log-transformed linear least-squares fit as previously described used (37). (C) 3D 
Myocardial BOLD Response: This panel shows 3D T2 maps (basal, mid-ventricular, and apical) acquired during normocapnia and 
hypercapnia (single stimulation block). For reference, results from 2D imaging obtained from a mid-ventricular slice are also shown. 
BOLD Response (computed as (hypercapnic myocardial T2  normocapnia myocardial T2) x100%) for the 2D and 3D cases are shown 
on the top panel. (D) Statistical Framework:  shows a schematic of the statistical framework employing repeated measures one-way 
ANOVA to discriminate between myocardial segments that are statistically responsive and not, based on the hypothesis testing 
outlined in text, following each repeat hypercapnic/normocapnic stimulation. The polar maps on the lower row show the AHA 
segmentation with p-values assigned on the statistical test. 
Figure. 5 Application of Cardiac fMRI Approach for Reliable Identification of Healthy Myocardium. (A) Myocardial Statistical 
Parametric Mapping (SPM): Long- and short-axis volume rendered views of the heart with intensities denoting segmental p-values 
derived from the statistical framework from a typical healthy animal are shown. The polar maps at the bottom of the panel provide a 
bull’s eye plot of p-values. (B) Myocardial SPM vs. 13N-Ammonia PET in Representative Case: Panel B1 shows the mean and 
standard deviation of p-values across all segments for the case in panel (A) as a function of number of stimulation blocks (one through 
four). Panel B2 shows the corresponding 13N-Ammonia PET MPR. (C) Myocardial SPM vs. 13N-Ammonia PET Across all Animals: 
Panel C1 shows the average response across all animals and all myocardial segments following one and four stimulations. Panel C2 
shows mean and scatter of MPR across all animals in response to hypercapnia. 
Fig. 6 Cardiac fMRI Based Statistical Parametric Mapping for Accurate Identification of Myocardial Segments Subtended by 
Clinically Significant Coronary Stenosis. (A) Myocardial Statistical Parametric Mapping Under Coronary Stenosis: Long- and 
short-axis volume rendered views of the heart with intensities denoting segmental p-values derived from the statistical framework 
from one dog with clinically significant coronary stenosis is shown. The polar maps at the bottom of the panel provide p-values for the 
AHA segments. (B) Myocardial SPM vs. 13N-Ammonia PET (for a representative case): Left panel shows the mean and standard 
deviation of p-values across affected and remote segments for the case in panel A as a function of number of stimulation blocks (one 
through four). Right panel shows the corresponding 13N-Ammonia PET MPR. (C) Myocardial SPM vs. 13N-Ammonia PET (for all 
cases): Left panel shows the average response across all animals in the affected and remote myocardial segments following one and 
four stimulations. Right panel shows the mean and scatter of PET-MPR across all animals in the remote and affected segments 
following hypercapnia. (D) Sensitivity, Specificity, and Accuracy: The results from sensitivity, specificity and accuracy determined 
following each stimulation (with PET serving as the ground truth) are shown in this panel. 
 
